IL130041A - Ferric citrate and/or ferric acetate for controlling phosphate retention in hyperphosphatemia patients - Google Patents

Ferric citrate and/or ferric acetate for controlling phosphate retention in hyperphosphatemia patients

Info

Publication number
IL130041A
IL130041A IL13004197A IL13004197A IL130041A IL 130041 A IL130041 A IL 130041A IL 13004197 A IL13004197 A IL 13004197A IL 13004197 A IL13004197 A IL 13004197A IL 130041 A IL130041 A IL 130041A
Authority
IL
Israel
Prior art keywords
ferric
patient
patients
acetate
hyperphosphatemia
Prior art date
Application number
IL13004197A
Other languages
English (en)
Other versions
IL130041A0 (en
Original Assignee
Chen Hsing Hsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26708838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Hsing Hsu filed Critical Chen Hsing Hsu
Publication of IL130041A0 publication Critical patent/IL130041A0/xx
Publication of IL130041A publication Critical patent/IL130041A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Liquid Crystal Substances (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL13004197A 1996-12-16 1997-11-14 Ferric citrate and/or ferric acetate for controlling phosphate retention in hyperphosphatemia patients IL130041A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3274596P 1996-12-16 1996-12-16
US08/794,328 US5753706A (en) 1996-12-16 1997-02-03 Methods for treating renal failure
PCT/US1997/020977 WO1998026776A1 (en) 1996-12-16 1997-11-14 Method for treating renal failure

Publications (2)

Publication Number Publication Date
IL130041A0 IL130041A0 (en) 2000-02-29
IL130041A true IL130041A (en) 2005-08-31

Family

ID=26708838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13004197A IL130041A (en) 1996-12-16 1997-11-14 Ferric citrate and/or ferric acetate for controlling phosphate retention in hyperphosphatemia patients

Country Status (12)

Country Link
US (1) US5753706A (de)
EP (1) EP0959878B1 (de)
JP (2) JP4173553B2 (de)
KR (1) KR100464504B1 (de)
AT (1) ATE400264T1 (de)
AU (1) AU723091B2 (de)
CA (1) CA2272711C (de)
DE (1) DE69738824D1 (de)
ES (1) ES2310417T3 (de)
IL (1) IL130041A (de)
NO (1) NO327148B1 (de)
WO (1) WO1998026776A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767851B2 (en) 2003-02-19 2010-08-03 Panion & Bf Biotech, Inc. Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
US9387191B2 (en) 2009-07-21 2016-07-12 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
US9750715B2 (en) 2006-01-30 2017-09-05 Panion & Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US20040020852A1 (en) * 2000-06-15 2004-02-05 Lars-Fride Olsson Method and apparatus for calcium profiling in dialysis
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US8592421B2 (en) 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
EP1830832A1 (de) * 2004-12-30 2007-09-12 Genzyme Corporation Zinkhaltige behandlungen für hyperphosphatämie
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1945196A2 (de) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesiumhaltige polymere für hyperphosphatämie
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
EP2043627A2 (de) * 2006-07-05 2009-04-08 Genzyme Corporation Eisen(ii)-haltige behandlungen für hyperphosphatämie
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
EP2194977A1 (de) * 2007-08-31 2010-06-16 C.B. Fleet Company Incorporated Verfahren zur prävention von nephrocalcinose
EP2334292B1 (de) * 2008-10-17 2019-05-08 Fresenius Medical Care Holdings, Inc. Verfahren zur bestimmung einer phosphorbinder-dosis für einen dialysepatienten
CN103800310A (zh) * 2008-10-27 2014-05-21 思佰益药业股份有限公司 以5-氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
JP5894533B2 (ja) * 2009-10-01 2016-03-30 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド リン−タンパク質比の計算方法
JP5167389B2 (ja) * 2010-07-07 2013-03-21 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤
JP2012162522A (ja) * 2011-01-18 2012-08-30 Japan Tobacco Inc β酸化水酸化鉄を実質的に含まないクエン酸第二鉄
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
EP3003327B1 (de) 2013-06-05 2017-08-09 Tricida Inc. Protonenbindende polymere zur oralen verabreichung
WO2015110968A1 (en) 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (de) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmazeutische zusammensetzungen mit eisencitrat und verfahren zur herstellung davon
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
JP6206420B2 (ja) * 2015-01-13 2017-10-04 テクノサイエンス株式会社 クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法
JP2018526349A (ja) 2015-08-05 2018-09-13 ルピン・リミテッド 医薬品グレードのクエン酸第二鉄の調製のためのプロセス
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP4347022A1 (de) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pädiatrische formulierungen von eisencitrat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1131360B (de) * 1957-11-26 1962-06-14 Vitarine Company Inc Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten
DE3228231A1 (de) * 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
JPH08198760A (ja) * 1995-01-20 1996-08-06 Japan Organo Co Ltd 経口用リン酸イオン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754258B2 (en) 2003-02-19 2014-06-17 Panion & Bf Biotech Inc. Ferric organic compounds, uses thereof and methods of making same
US9328133B2 (en) 2003-02-19 2016-05-03 Panion & Bf Biotech Inc. Ferric organic compounds, uses thereof and methods of making same
US8299298B2 (en) 2003-02-19 2012-10-30 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
US8338642B2 (en) 2003-02-19 2012-12-25 Panion & Bf Biotech, Inc. Ferric organic compounds, uses thereof and methods of making same
US8609896B2 (en) 2003-02-19 2013-12-17 Panion & Bf Biotech Inc. Ferric organic compounds, uses thereof and methods of making same
US8754257B2 (en) 2003-02-19 2014-06-17 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US8901349B2 (en) 2003-02-19 2014-12-02 Panion & Bf Biotech Inc. Ferric organic compounds, uses thereof and methods of making same
US9757416B2 (en) 2003-02-19 2017-09-12 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
US9050316B2 (en) 2003-02-19 2015-06-09 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US7767851B2 (en) 2003-02-19 2010-08-03 Panion & Bf Biotech, Inc. Ferric organic compounds, uses thereof and methods of making same
US8846976B2 (en) 2003-02-19 2014-09-30 Panion & Bf Biotech Inc. Ferric organic compounds, uses thereof and methods of making same
US9750715B2 (en) 2006-01-30 2017-09-05 Panion & Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification
US9387191B2 (en) 2009-07-21 2016-07-12 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms

Also Published As

Publication number Publication date
KR100464504B1 (ko) 2004-12-31
NO992936L (no) 1999-08-13
KR20000069414A (ko) 2000-11-25
NO992936D0 (no) 1999-06-16
EP0959878A4 (de) 2002-03-27
JP2007217429A (ja) 2007-08-30
IL130041A0 (en) 2000-02-29
US5753706A (en) 1998-05-19
JP4173553B2 (ja) 2008-10-29
CA2272711C (en) 2008-04-29
CA2272711A1 (en) 1998-06-25
DE69738824D1 (de) 2008-08-21
ES2310417T3 (es) 2009-01-01
WO1998026776A1 (en) 1998-06-25
ATE400264T1 (de) 2008-07-15
JP2001506262A (ja) 2001-05-15
AU723091B2 (en) 2000-08-17
EP0959878B1 (de) 2008-07-09
AU5441998A (en) 1998-07-15
NO327148B1 (no) 2009-05-04
EP0959878A1 (de) 1999-12-01

Similar Documents

Publication Publication Date Title
IL130041A (en) Ferric citrate and/or ferric acetate for controlling phosphate retention in hyperphosphatemia patients
Lockwood et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
Gilbert et al. Prevention of acute aspirin-induced gastric mucosal injury by 15-R-15 methyl prostaglandin E2: an endoscopic study
Owada et al. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study.
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
CA2238040A1 (en) Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications
Zinberg et al. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
Madsen et al. Acute propoxyphene self‐poisoning in 222 consecutive patients
WO2003011225A3 (en) Calcium glutarate supplement and phosphorus binder
Birger Jensen et al. Prophylactic effect of cimetidine in gastric ulcer patients
EP0425298A3 (en) Sustained-release preparation of basic medical agent hydrochloride
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
AU569840B2 (en) Use of oleanolic acid for ulcer treatment
Hautmann et al. Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria
Reissell et al. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides
Sweany et al. A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis
Atkinson et al. Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions
HUT57595A (en) Process for producing orally administrable pharmaceutical composition having bone strengthening effect
Williams Clinical Experience with 5‐Aminosalicylate Preparations in Inflammatory Bowel Disease‐A Review
Rizhik et al. Possibilities of computerized tomography method in determination of choledoch permeability
Pinto et al. Five-Year Treatment in Hyperoxaluric Stone Formers
Vaziri et al. Hyperoxaluria in chronic renal disease associated with spinal cord injury
Abboud Nephrolithiasis in Patients with Gastrointestinal Disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired